Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by chipmuki1234567on Feb 28, 2018 7:54am

91 Views

Post# 27634373

RE:RE:RE:RE:RE:RE:RE:RE:Financials are out in SEDAR; no News Release so far

nope my mental health is fine and I am not trying to drive the share price down. I own quite a lot of shares and have been in this company before the disaster of the phase 1 trials. Recently we got a bunch of new commentators as this trial is close to being done, and they are peddling management's lies. I tend to do my research and stay honest on what I find on that research. I am telling all of you to judge this management for what they are... Big promises and sloppy execution.

Bullboard Posts

Unique Battery Metals opportunity in Quebec